Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (5117)	11/16/2003 2:21:40 PM
From: Cacaito	Read Replies (1) \| Respond to of 10345

" potential drugs for Az's will live or die on their own" But, the eliminate amyloid beta protein approach to help Az patients is only a nice theory with strong animal test data, the human data confirmation of the theory is very important, there are many contradictory theories (all with very good animal models) about what to do with the amyloid protein. Some considered the elimination harmful, some wants to provide the normal variant, some wants to eliminate the abnormal amyloid protein. If the full data from the halted Az1792 trial shows a confirmation of benefits (strongly suggested by the German subgroup) the "new potentials will live or die on their own" but the stock price will (be) lift by Az1792. But, if the market does not care about proven efficacy from the Az1792 trial (safety wise is already a failure), it will make it easier for me to load more.